Larance B - Search Results

1

Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.

Settumba S, Shahbazi J, Byrne M, Degenhardt L, Grebely J, Larance B, Nielsen S, Lintzeris N, Ali R, Rodgers C, Blazey A, Weiss R, Dunlop A, McDonough M, Cook J, Farrell M. Settumba S, et al. Among authors: larance b. Drug Alcohol Rev. 2024 Oct 6. doi: 10.1111/dar.13956. Online ahead of print. Drug Alcohol Rev. 2024. PMID: 39370671

2

Drug dependence and associated risks among female street-based sex workers in the greater Sydney area, Australia.

Roxburgh A, Degenhardt L, Copeland J, Larance B. Roxburgh A, et al. Among authors: larance b. Subst Use Misuse. 2008 Jul;43(8-9):1202-17. doi: 10.1080/10826080801914410. Subst Use Misuse. 2008. PMID: 18649239

3

Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.

Larance B, Degenhardt L, Copeland J, Dillon P. Larance B, et al. Drug Alcohol Rev. 2008 Nov;27(6):679-86. doi: 10.1080/09595230802392568. Drug Alcohol Rev. 2008. PMID: 18825549

4

Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.

Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP. Degenhardt L, et al. Med J Aust. 2009 Aug 3;191(3):161-5. doi: 10.5694/j.1326-5377.2009.tb02729.x. Med J Aust. 2009. PMID: 19645647

5

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.

Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L. Horyniak D, et al. Among authors: larance b. Int J Drug Policy. 2011 Mar;22(2):167-71. doi: 10.1016/j.drugpo.2010.10.004. Epub 2010 Nov 27. Int J Drug Policy. 2011. PMID: 21112758

6

Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.

Larance B, Degenhardt L, O'Brien S, Lintzeris N, Winstock A, Mattick RP, Bell J, Ali R. Larance B, et al. Drug Alcohol Rev. 2011 Nov;30(6):613-20. doi: 10.1111/j.1465-3362.2010.00274.x. Epub 2011 Jan 5. Drug Alcohol Rev. 2011. PMID: 21355939

7

Larance B, Degenhardt L, Lintzeris N, Winstock A, Mattick R. Larance B, et al. Drug Alcohol Rev. 2011 May;30(3):236-45. doi: 10.1111/j.1465-3362.2010.00283.x. Drug Alcohol Rev. 2011. PMID: 21545553 Review.

8

The availability, diversion and injection of pharmaceutical opioids in South Asia.

Larance B, Ambekar A, Azim T, Murthy P, Panda S, Degenhardt L, Mathers B. Larance B, et al. Drug Alcohol Rev. 2011 May;30(3):246-54. doi: 10.1111/j.1465-3362.2011.00304.x. Drug Alcohol Rev. 2011. PMID: 21545554 Review.

9

Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

Larance B, Degenhardt L, Lintzeris N, Bell J, Winstock A, Dietze P, Mattick R, Ali R, Horyniak D. Larance B, et al. Drug Alcohol Depend. 2011 Nov 1;118(2-3):265-73. doi: 10.1016/j.drugalcdep.2011.04.002. Epub 2011 May 12. Drug Alcohol Depend. 2011. PMID: 21565452

10

A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.

Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR, Holland RM, Degenhardt L, Muhleisen P, Hurley M, Ali R. Lintzeris N, et al. Among authors: larance b. Drug Alcohol Depend. 2013 Jul 1;131(1-2):119-26. doi: 10.1016/j.drugalcdep.2012.12.009. Epub 2013 Jan 12. Drug Alcohol Depend. 2013. PMID: 23317685 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters